Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Grows By 154.5%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 11,200 shares, an increase of 154.5% from the January 31st total of 4,400 shares. Based on an average daily trading volume, of 10,100 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Large investors have recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new stake in ProShares Ultra Nasdaq Biotechnology during the 4th quarter valued at $51,000. Tower Research Capital LLC TRC boosted its position in ProShares Ultra Nasdaq Biotechnology by 31.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund’s stock worth $270,000 after acquiring an additional 1,266 shares during the period. Finally, Jane Street Group LLC boosted its position in ProShares Ultra Nasdaq Biotechnology by 8.4% during the 3rd quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund’s stock worth $306,000 after acquiring an additional 374 shares during the period.

ProShares Ultra Nasdaq Biotechnology Stock Up 2.6 %

NASDAQ:BIB opened at $55.00 on Friday. ProShares Ultra Nasdaq Biotechnology has a 52 week low of $47.19 and a 52 week high of $69.56. The business’s 50 day moving average is $53.54 and its two-hundred day moving average is $59.07.

ProShares Ultra Nasdaq Biotechnology Increases Dividend

The business also recently announced a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were issued a dividend of $0.3964 per share. The ex-dividend date was Monday, December 23rd. This is a positive change from ProShares Ultra Nasdaq Biotechnology’s previous dividend of $0.15.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.